Helium induced organ protection and the role of circulatory factors: secretion of Caveolin to the bloodstream (HeCav) in humans.
Completed
- Conditions
- cardioprotection10082206organprotection
- Registration Number
- NL-OMON40987
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Non-smoking, healthy, male volunteers aged 20-55 years.
Exclusion Criteria
1. Active smoking or smoking in the 6 months previous to the
investigation;
2. Alcohol abuse or use of recreational drugs
3. Any allergic reaction on medication in the past
4. Presence of a chronic disease that is under current medical
observation and needs pharmacological treatment, e.g. asthma, high
blood pressure or diabetes
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main endpoints of this study are measuring cell damage by way of LDH<br /><br>measurements and apoptosis (eg caspase 3/8/9 activity, tunnel staining) in<br /><br>Human Umbilical Vein Endothelial Cells, Human Coronary Artery Endothelial Cells<br /><br>and rat cardiomyocytes against hypoxic induced damage by serum taken from the<br /><br>volunteers. Furthermore, the expression levels of Caveolin 1 and 3 in serum of<br /><br>the volunteers will be determined. </p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>